文献速递治疗药物监测与药物基因组学药物相互作用特殊人群用药

质子泵抑制剂和/或类固醇联用或为血液恶性肿瘤成人患者泊沙康唑缓释片低谷浓度危险因素

Co-administration of proton pump inhibitors and/or of steroids may be a risk factor for low trough concentrations of posaconazole delayed-released tablets in adult patients with haematological malignancies.
PubMed 文献 · Br J Clin Pharmacol · 2018-08-19

本研究纳入66例接受泊沙康唑缓释片预防侵袭性真菌感染的血液恶性肿瘤成人患者,共176次谷浓度监测。33.3%患者至少一次谷浓度低于0.7 mg/l,多因素分析显示PPI使用、中高剂量类固醇使用及男性与谷浓度降低显著相关,而治疗起始时间与谷浓度升高相关。

要点

  • 泊沙康唑缓释片预防时,33.3%患者至少一次谷浓度低于0.7 mg/l。
  • 联用PPI或中高剂量类固醇(>0.7 mg/kg/日)与谷浓度降低显著相关。
  • 男性性别与谷浓度降低相关,治疗起始时间与谷浓度升高相关。

核心结论

  • 泊沙康唑缓释片治疗期间暴露可能受PPI和/或中高剂量类固醇使用影响。

主要发现

  • 33.3%的患者(22/66)至少一次出现泊沙康唑谷浓度低于0.7 mg/l,总体17.0%的治疗药物监测 episodes(30/176)低于该阈值。
  • 多水平线性回归显示,PPI使用(P=0.008)、中高剂量类固醇使用(>0.7 mg/kg/日)(P=0.022)及男性性别(P=0.025)与谷浓度降低显著相关。
  • 治疗起始时间(P=0.032)与谷浓度升高显著相关。

临床怎么用

  • 对接受泊沙康唑缓释片预防的血液恶性肿瘤成人患者,应关注PPI及中高剂量类固醇联用对谷浓度的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The aim of this study was to determine clinical variables associated with posaconazole exposure among adult patients with haematological malignancies who received posaconazole tablets for prophylaxis of invasive fungal infections (IFIs). METHODS: The study population included adult patients with haematological malignancies who received posaconazole delayed-release tablets for prophylaxis of IFIs after induction chemotherapy for acute leukaemia or graft-versus-host-disease (GVHD) complicating hematopoietic stem cell transplantation (HSCT) in the period January 2016-December 2017. RESULTS: Sixty-six consecutive patients with 176 posaconazole Cmin were included for evaluation in the study. Subtherapeutic posaconazole concentrations (< 0.7 mg l-1 ) were observed at least once in 33.3% of patients (22/66), and overall in 17.0% of therapeutic drug monitoring (TDM) episodes (30/176). At multilevel linear regression, use of PPIs (P = 0.008), use of intermediate or high dose steroids (>0.7 mg kg-1 daily) (P = 0.022) and male gender (P = 0.025) were significantly associated with decreased Cmin , whereas time from starting therapy (P = 0.032) was associated with increased Cmin in our patient population. CONCLUSION: Posaconazole exposure during treatment with delayed-released tablet formulation may be affected by the use of PPIs and/or of intermediate or high dose steroids.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Cojutti PG, Candoni A, Lazzarotto D, et al. Co-administration of proton pump inhibitors and/or of steroids may be a risk factor for low trough concentrations of posaconazole delayed-released tablets in adult patients with haematological malignancies. Br J Clin Pharmacol. 2018. PMID: 29975796. doi:10.1111/bcp.13707

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。